SCHEMBL736693

SCHEMBL736693

CCCNS(C)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4700590 0.97
Dimethylamine SCHEMBL20946169 0.94 CA1 (0.57)
SCHEMBL1235922 0.84 CA1 (0.46)
SCHEMBL3043384 0.83 POLB (0.44)
SCHEMBL487521 0.82
SCHEMBL327308 0.80 PPARA (0.60)
SCHEMBL11512340 0.80 CA1 (0.64)
SCHEMBL21985682 0.80 CA1 (0.44)
SCHEMBL15672976 0.79 CA1 (0.60)
SCHEMBL11326328 0.78 PPARA (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694505-B1 HSP90 INHIBITORS SLOAN KETTERING INST CANCER RES (US) 2022-04-27 EP claimed
US-10201623-B2 HSP90-targeted cardiac imaging and therapy MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2019-02-12 US claimed
US-20160264577-A1 HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2016-09-15 US claimed
US-20140088121-A1 HSP90 Inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2014-03-27 US claimed
EP-2694505-A1 HSP90 INHIBITORS Sloan-kettering Institute For Cancer Research (US) 2014-02-12 EP claimed
WO-2012138894-A1 HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-10-11 WO claimed
JP-4537315-B2 2010-09-01 JP claimed
US-20100173906-A1 Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-Tetraazacyclopenta[cd]Phenalenes and Methods 3M INNOVATIVE PROPERTIES COMPANY 2010-07-08 US claimed
US-7666863-B2 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases VIROPHARMA INCORPORATED (US) 2010-02-23 US claimed
US-7560460-B2 Substituted piperazines and methods of use AMGEN INC. (US) 2009-07-14 US claimed
EP-1416933-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR Amgem, Inc. (US) 2004-05-12 EP claimed
EP-1417190-A1 SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR Amgen Inc. (US) 2004-05-12 EP claimed
US-20040006067-A1 Substituted piperidines and methods of use AMGEN INC. 2004-01-08 US claimed
US-20030220324-A1 Substituted piperazines and methods of use AMGEN INC. 2003-11-27 US claimed
WO-2003009847-A1 SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR AMGEM, INC. (US) 2003-02-06 WO claimed
WO-2003009850-A1 SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR AMGEN INC. (US) 2003-02-06 WO claimed
EP-0120637-B1 BENZOQUINOLIZINES JOHN WYETH &amp; BROTHER LIMITED (GB) 1988-01-20 EP claimed
EP-0074894-B1 PROCESS FOR THE PURIFICATION OF A GASEOUS MIXTURE CONTAINING UNDESIRABLE GASEOUS COMPOUNDS COMPAGNIE FRANCAISE DE RAFFINAGE Société anonyme dite: (FR) 1985-01-02 EP claimed
EP-0074894-A1 Process for the purification of a gaseous mixture containing undesirable gaseous compounds COMPAGNIE FRANCAISE DE RAFFINAGE Société anonyme dite: (FR) 1983-03-23 EP claimed
US-4170547-A SOLVENT EXTRACTION COMPAGNIE FRANCAISE DE RAFFINAGE (FR) 1979-10-09 US claimed